Loop Industries, Inc. (LOOP)
Live price chart, market sentiment, and community perspectives for Loop Industries, Inc. (NASDAQ: LOOP).
Live price chart, market sentiment, and community perspectives for Loop Industries, Inc. (NASDAQ: LOOP).
On our desk, LOOP is flashing absolute red flags on liquidity. With cash reserves dwindling down to roughly $1.063 million against ongoing quarterly operating burn and missed revenue forecasts, survival entirely depends on securing external capital. The market is pricing in imminent, highly dilutive equity offerings, making any near-term upside very difficult to justify from a pure risk-reward standpoint.
Looking at the technical profile, the 50-day moving average at $0.97 and 200-day moving average at $1.19 are clearly acting as heavy overhead resistance. Trading down near $0.72-0.84 with a beta of 1.45, the stock shows high downward momentum following the fiscal Q1 revenue miss. Without an unexpected institutional bailout or immediate commercial scaling, short-side bias remains structurally intact.
From a chemical engineering and technology validation perspective, the Infinite Loop depolymerization process at the Terrebonne facility is innovative on paper, but the company remains stuck in the development stage. Translating lab-scale processes to commercial viability in external markets like the India joint venture (ELITe) introduces massive operational execution hurdles and extended timelines before meaningful royalties materialize.
Zacks Research dropping LOOP to a 'Strong Sell' lines up with our internal multi-model consensus where 0 of 2 models project upside at these levels. The Quality Score of 5.0/10 underlines weak fundamental execution. Even though long-term royalty deals tied to a $500M sales target in India sound attractive in an 8-K filing, near-term insolvency risks totally overshadow future revenue promises.
On our risk management desk, we are flagging the explicit 'going concern' warning noted in the recent 10-K filing. Existing cash and undrawn credit facilities are insufficient for the next twelve months. Commercial inflection simply did not happen in Q1, with revenue dropping to $179,000 versus expectations near $918,000. Position sizing must account for potential wipeout or severe dilution.
Explore plasma cleansing, somatic organ swaps, and BCI.